Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stuart Roger Lipsitz, Sc.D.

Co-Author

Back to Details
This page shows the publications co-authored by Stuart Lipsitz and Adam Kibel.
Stuart Lipsitz
Connection Strength
2.667
Adam Kibel
  1. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
    View in: PubMed
    Score: 0.205
  2. Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncol Pract. 2021 05; 17(5):e654-e665.
    View in: PubMed
    Score: 0.058
  3. Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer? J Comp Eff Res. 2021 06; 10(9):733-741.
    View in: PubMed
    Score: 0.058
  4. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 07; 39(7):436.e1-436.e10.
    View in: PubMed
    Score: 0.058
  5. Reply by Authors. J Urol. 2021 05; 205(5):1274.
    View in: PubMed
    Score: 0.058
  6. Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021 May; 205(5):1263-1274.
    View in: PubMed
    Score: 0.057
  7. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.054
  8. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urol Oncol. 2020 03; 38(3):74.e13-74.e20.
    View in: PubMed
    Score: 0.053
  9. Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun; 27(6):1929-1936.
    View in: PubMed
    Score: 0.053
  10. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.053
  11. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289.
    View in: PubMed
    Score: 0.053
  12. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.052
  13. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
    View in: PubMed
    Score: 0.051
  14. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 01; 7(1):124-131.
    View in: PubMed
    Score: 0.051
  15. Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 05 03; 2(5):e194634.
    View in: PubMed
    Score: 0.051
  16. The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
    View in: PubMed
    Score: 0.051
  17. Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. J Oncol Pract. 2019 06; 15(6):e547-e559.
    View in: PubMed
    Score: 0.051
  18. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.051
  19. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.051
  20. Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Netw Open. 2019 02 01; 2(2):e187633.
    View in: PubMed
    Score: 0.050
  21. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
    View in: PubMed
    Score: 0.050
  22. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 06; 17(3):e488-e493.
    View in: PubMed
    Score: 0.050
  23. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.050
  24. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
    View in: PubMed
    Score: 0.050
  25. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.049
  26. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
    View in: PubMed
    Score: 0.049
  27. Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
    View in: PubMed
    Score: 0.049
  28. Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference? Eur Urol Oncol. 2019 07; 2(4):349-354.
    View in: PubMed
    Score: 0.049
  29. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.049
  30. Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Can Urol Assoc J. 2019 Feb; 13(2):32-37.
    View in: PubMed
    Score: 0.048
  31. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.047
  32. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.047
  33. Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321.
    View in: PubMed
    Score: 0.047
  34. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.047
  35. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
    View in: PubMed
    Score: 0.046
  36. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urol Oncol. 2018 02; 36(2):78.e13-78.e19.
    View in: PubMed
    Score: 0.046
  37. Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436.
    View in: PubMed
    Score: 0.046
  38. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.045
  39. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
    View in: PubMed
    Score: 0.045
  40. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.045
  41. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.045
  42. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068.
    View in: PubMed
    Score: 0.044
  43. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.044
  44. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
    View in: PubMed
    Score: 0.043
  45. The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am J Surg. 2017 Nov; 214(5):871-883.
    View in: PubMed
    Score: 0.043
  46. Prog Urol. 2016 Nov; 26(13):676-677.
    View in: PubMed
    Score: 0.043
  47. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.043
  48. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.042
  49. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.041
  50. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.040
  51. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
    View in: PubMed
    Score: 0.035
  52. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.